Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Research article

Protective effect of quinacrine against glycerol-induced acute kidney injury in rats

Authors: Abdulrahman K. Al Asmari, Khalid Tariq Al Sadoon, Ali Ahmed Obaid, Deivakadatcham Yesunayagam, Mohammad Tariq

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

Background

Acute kidney injury (AKI) is a serious clinical problem with high rate of mortality and morbidity. Currently used prophylactic and therapeutic strategies to address AKI are limited and warrant further studies. In the present study an attempt was made to investigate the effect of quinacrine, a phospholipase A2 inhibitor against glycerol induced AKI in rats.

Methods

Adult female Wistar rats were divided in to five groups. After 24 h of water deprivation rats in groups 3, 4 and 5 received an intraperitoneal injection of quinacrine (3 mg/kg, 10 mg/kg and 30 mg/kg of body weight respectively). Thirty minutes after the first injection of quinacrine animals in groups 3, 4 and 5 received an intramuscular injection of 25% glycerol (10 ml/kg of body weight). The animals in group 2 received 25% glycerol (10 ml/kg of body weight) only whereas rats in group 1 served as control . The quinacrine administration was continued once daily for three days, on the fourth day animals were sacrificed, blood and kidney were collected for various biochemical and histopathological studies.

Results

Glycerol treatment produced significant renal structural abnormalities and functional impairment (increased urea and creatinine). Increase in myeloperoxidase (MPO) and malondialdehyde (MDA) clearly suggested the involvement of oxidative stress and neutrophilic activity following glycerol administration. Quinacrine dose dependently attenuated glycerol induced structural and functional changes in kidney.

Conclusion

The reversal of glycerol induced AKI by quinacrine points towards a role of phospholipase A2 (PLA2) in the pathogenesis of renal injury. The result of this study suggests that quinacrine may offer an alternative mode of treatment for AKI.
Literature
1.
Liaño F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int. 1996;50(3):811–8.CrossRefPubMed
2.
Wilson DR, Thiel G, Arce ML, Oken DE. Glycerol induced hemoglobinuric acute renal failure in the rat. 3. Micropuncture study of the effects of mannitol and isotonic saline on individual nephron function. Arce Nephron. 1967;4(6):337–55.CrossRefPubMed
3.
Abul-Ezz SR, Walker PD, Shah SV. Role of glutathione in an animal model of myoglobinuric acute renal failure. Proc Natl Acad Sci U S A. 1991;88(21):9833–7.CrossRefPubMedPubMedCentral
4.
Chander V, Chopra K. Molsidomine a nitric oxide donor and L-arginine protects against rhabdomyolysis-induced myoglobinuric acute renal failure. Biochim Biophys Acta. 2005;1723(1–3):208–14.CrossRefPubMed
5.
Malik GH. Rhabdomyolysis and myoglobin-induced acute renal failure. Saudi J Kidney Dis Transpl. 1998;9(3):273–84.PubMed
6.
Efstratiadis G, Voulgaridou A, Nikiforou D, Kyventidis A, Kourkouni E, Vergoulas G. Rhabdomyolysis updated. Hippokratia. 2007;11(3):129–37.PubMedPubMedCentral
7.
Hsu CH, Kurtz TW, Waldinger TP. Cardiac output and renal blood flow in glycerol-induced acute renal failure in the rat. Circ Res. 1977;40(2):178–82.CrossRefPubMed
8.
Zager RA, Burkhart KM, Conrad DS, Gmur DJ, Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 1996;49(2):314–26.CrossRefPubMed
9.
Zager RA, Burkhart KM, Conrad DS, Gmur DJ. Iron, hemeoxygenase, and glutathione: effects on myohemoglobinuric proximal tubular injury. Kidney Int. 1995;48(5):1624–34.CrossRefPubMed
10.
Zager RA, Burkhart KM. Differential effects of glutathione and cysteine on Fe2+, Fe3+, H2O2 and myoglobin-induced proximal tubular cell attack. Kidney Int. 1998;53(6):1661–72.CrossRefPubMed
11.
Moore KP, et al. A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J Biol Chem. 1998;273(48):31731–7.CrossRefPubMed
12.
Homsi E, Janino P, de Faria JB. Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int. 2006;69(8):1385–92.CrossRefPubMed
13.
Zager RA, Sacks BM, Burkhart KM, Williams AC. Plasma membrane phospholipid integrity and orientation during hypoxic and toxic proximal tubular attack. Kidney Int. 1999;56(1):104–17.CrossRefPubMed
14.
Farber JL, Chien KR, Mittnacht Jr S. Myocardial ischemia: the pathogenesis of irreversible cell injury in ischemia. Am J Pathol. 1981;102(2):271–81.PubMedPubMedCentral
15.
Humes HD, Jackson NM, O’Connor RP, Hunt DA, White MD. Pathogenetic mechanisms of nephrotoxicity: insights into cyclosporine nephrotoxicity. Transplant Proc. 1985;17(4 Suppl 1):51–62.PubMed
16.
Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science. 1972;175(4023):720–31.CrossRefPubMed
17.
Rubalcava B, Rodbell M. The role of acidic phospholipids in glucagon action on rat liver adenylate cyclase. J Biol Chem. 1973;248(11):3831–7.PubMed
18.
Dahl JL, Hokin LE. The sodium-potassium adenosine-triphosphatase. Annu Rev Biochem. 1974;43:327–55.CrossRefPubMed
19.
Cullis PR, deKruijff B, Hope MJ, Nayar R. Phospholipids and membrane transport. Can J Biochem. 1980;58:1091–100.CrossRefPubMed
20.
Green DE, Fry M, Blondin GA. Phospholipids as the molecular instruments of ion and solute transport in biological membranes. Proc Natl Acad Sci U S A. 1980;77(1):257–61.CrossRefPubMedPubMedCentral
21.
Chien KR, Abrams J, Serroni A, Martin JT, Farber JL. Accelerated phospholipid degradation and associated membrane dysfunction in irreversible, ischemic liver cell injury. J Biol Chem. 1978;253(13):4809–17.PubMed
22.
Chien KR, Reeves JP, Buja LM, Bonte F, Parkey RW, Willerson JT. Phospholipid alterations in canine ischemic myocardium. Temporal and topographical correlations with Tc-99 m-PPi accumulation and an in vitro sarcolemmal Ca + 2 permeability defect. Circ Res. 1981;48(5):711–9.CrossRefPubMed
23.
Matthys E, Patel Y, Kreisberg J, Stewart JH, Venkatachalam M. Lipid alterations induced by renal ischemia: pathogenic factor in membrane damage. Kidney Int. 1984;26(2):153–61.CrossRefPubMed
24.
Lee JC, Simonyi A, Sun AY, Sun GY. Phospholipases A2 and neural membrane dynami cs: implications for Alzheimer’s disease. J Neurochem. 2011;116(5):813–9.CrossRefPubMedPubMedCentral
25.
26.
Dennis EA, Rhee SG, Billah MM, Hannun YA. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J. 1991;5(7):2068–77.PubMed
27.
Vigo C, Lewis GP, Piper PJ. Mechanisms of inhibition of phospholipase A2. Biochem Pharmacol. 1980;29(4):623–7.CrossRefPubMed
28.
Korrapati MC, Shaner BE, Schnellmann RG. Recovery from glycerol-induced acute kidney injury is accelerated by suramin. J Pharmacol Exp Ther. 2012;341(1):126–36.CrossRefPubMedPubMedCentral
29.
30.
Barone FC, Hillegass LM, Price WJ, White RF, Lee EV, Feuerstein GZ, Sarau HM, Clark RK, Griswold DE. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. J Neurosci Res. 1991;29(3):336–45.CrossRefPubMed
31.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–8.CrossRefPubMed
32.
Ustundag S, Sen S, Yalcin O, Ciftci S, Demirkan B, Ture M. L-Carnitine ameliorates glycerol-induced myoglobinuric acute renal failure in rats. Ren Fail. 2009;31(2):124–33.CrossRefPubMed
33.
Bowmer CJ, Collis MG, Yates MS. Effect of the adenosine antagonist 8-phenyltheophylline on glycerol-induced acute renal failure in the rat. Br J Pharmacol. 1986;88(1):205–12.CrossRefPubMedPubMedCentral
34.
Al Khader A, al Sulaiman M, Kishore PN, Morais C, Tariq M. Quinacrine attenuates cyclosporine-induced nephrotoxicity in rats. Transplantation. 1996;62(4):427–35.CrossRefPubMed
35.
Al Moutaery AR, Tariq M. Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers. Digestion. 1997;58(2):129–37.CrossRefPubMed
36.
Tariq M, Khan HA, Al Moutaery K, Al DS. Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents. Brain Res Bull. 2001;54(1):77–82.CrossRefPubMed
37.
Chiariello M, Ambrosio G, Cappelli-Bigazzi M, Nevola E, Perrone-Filardi P, Marone G, Condorelli M. Inhibition of ischemia-induced phospholipase activation by quinacrine protects jeopardized myocardium in rats with coronary artery occlusion. J Pharmacol Exp Ther. 1987;241(2):560–8.PubMed
38.
Phillis JW. Cerebroprotective action of the phospholipase inhibitor quinacrine in the ischemia/reperfused gerbil hippocampus. Life Sci. 1996;58(6):L97–101.CrossRef
39.
Estevez AY, Phillis J. The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. Brain Res. 1997;752(1–2):203–8.CrossRefPubMed
40.
41.
Duan SB, Liu FY, Luo JA, Wu HW, Liu RH, Peng YM, Yang XL. Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model. Acta Radiol. 2000;41(5):503–7.PubMed
42.
Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem. 1994;269(18):13057–60.PubMed
43.
Balsinde J, Winstead MV, Dennis EA. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett. 2002;531(1):2–6.CrossRefPubMed
44.
Watson AJ, Stout RL, Adkinson Jr NF, Solez K, Whelton A. Selective inhibition of thromboxane synthesis in glycerol-induced acute renal failure. Am J Kidney Dis. 1986;8(1):26–30.CrossRefPubMed
45.
Hatziantoniou C, Papanikolaou N. Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046. Experientia. 1986;42(6):613–5.CrossRefPubMed
46.
Xu N. Effect of electroacupuncture at “taixi” point on plasma thromboxane A2 and prostacyclin in the rabbit with renal ischemia. Zhen Ci Yan Jiu. 1993;18(3):240–2.PubMed
47.
Gao JT, Liu SH, Yan YE, Wu Y, Wu HT, Xing C, Ge XM, Wang H, Zhao YQ, Fan M. Quinacrine protects neuronal cells against heat-induced injury. Cell Biol Int. 2009;33(8):874–81.CrossRefPubMed
48.
Erman A, Azuri R, Raz A. Prostaglandin biosynthesis in rabbit kidney: mepacrine inhibits renomedullary cyclooxygenase. Biochem Pharmacol. 1984;33(1):79–82.CrossRefPubMed
49.
Limas C, Limas CJ. Enhanced renomedullary prostaglandin synthesis in spontaneously hypertensive rats: role of a phospholipase A2. Am J Physiol. 1979;236(1):H65–72.PubMed
50.
Raz A. Mepacrine blockade of arachidonate-induced washed platelet aggregation: relationship to mepacrine inhibition of platelet cyclooxygenase. Thromb Haemost. 1983;50(4):784–6.PubMed
51.
Bank N, Aynedjian HS. Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats. J Clin Invest. 1992;89(5):1636–42.CrossRefPubMedPubMedCentral
52.
Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009;2009:137072. Epub 2010 Feb 21.CrossRefPubMed
53.
Deng LL, Zhong L, Lei JR, Tang L, Liu L, Xie SQ, Liao XH. Protective effect of lipoxin A4 against rhabdomyolysis-induced acute kidney injury in rats. Xi Bao Yu Fen ZiMian Yi XueZaZhi. 2012;28(9):907–10.
54.
Bolisetty S, Agarwal A. Neutrophils in acute kidney injury: not neutral any more. Kidney Int. 2009;75(7):674–6.CrossRefPubMed
55.
Takasaki J, Kawauchi Y, Urasaki T, Tanaka H, Usuda S, Masuho Y. Antibodies against type II phospholipase A2 prevent renal injury due to ischemia and reperfusion in rats. FEBS Lett. 1998;440(3):377–81.CrossRefPubMed
56.
Daniels I, Lindsay MA, Keany CI, Burden RP, Fletcher J, Haynes AP. Role of arachidonic acid and its metabolites in the priming of NADPH oxidase in human polymorphonuclear leukocytes by peritoneal dialysis effluent. Clin Diagn Lab Immunol. 1998;5(5):683–9.PubMedPubMedCentral
57.
Kramer RM, Hession C, Johansen B, Hayes G, McGray P, Chow EP, Tizard R, Pepinsky RB. Structure and properties of a human non-pancreatic phospholipase A2. J Biol Chem. 1989;264(10):5768–75.PubMed
58.
Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol. 2014;9:181–218.CrossRefPubMed
59.
60.
Dagher PC, Mai EM, Hato T, Lee SY, Anderson MD, Karozos SC, Mang HE, Knipe NL, Plotkin Z, Sutton TA. The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury. Am J Physiol Ren Physiol. 2012;302(2):F284–91.CrossRef
61.
62.
Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan ML, Golovkina TV, Rokhlin OW, Kuprash DV, Nedospasov SA, Hazen SL, Feinstein E, Gudkov AV. p53 is a suppressor of inflammatory response in mice. FASEB J. 2005;19(8):1030–2.PubMed
63.
64.
Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, Gurova KV. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med. 2011;3(95):95ra74.CrossRefPubMed
65.
Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther. 2014;13(9):2203–14.CrossRefPubMed
66.
Horton JR, Sawada K, Nishibori M, Zhang X, Cheng X. Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure. 2001;9(9):837–49.CrossRefPubMedPubMedCentral
67.
Radke KJ, Selkurt EE, Willis LR. The role of histamine H1 and H2 receptors in the canine kidney. Ren Physiol. 1985;8(2):100–11.PubMed
68.
Jutel M, Blaser K, Akdis CA. Histamine in allergic inflammation and immune modulation. Int Arch Allergy Immunol. 2005;137(1):82–92. Epub 2005 Apr 12.CrossRefPubMed
69.
Hiraga N, Adachi N, Liu K, Nagaro T, Arai T. Suppression of inflammatory cell recruitment by histamine receptor stimulation in ischemic rat brains. Eur J Pharmacol. 2007;557(2–3):236–44. Epub 2006 Nov 14.CrossRefPubMed
70.
Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;533(1–3):69–76. Epub 2006 Jan 31.CrossRefPubMed
71.
Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A. 2005;102(48):17448–53.CrossRefPubMedPubMedCentral
72.
Park CH, Tanaka T, Cho EJ, Park JC, Shibahara N, Yokozawa T. Glycerol-induced renal damage improved by 7-O-galloyl-D-sedoheptulose treatment through attenuating oxidative stress. Biol Pharm Bull. 2012;35(1):34–41.CrossRefPubMed
73.
74.
Turnbull S, Tabner BJ, Brown DR, Allsop D. Quinacrine acts as an antioxidant and reduces the toxicity of the prion peptide PrP106-126. Neuroreport. 2003;14(13):1743–5.CrossRefPubMed
75.
Nagai J, Tanaka M, Hibasami H, Ikeda T. Inhibition of oxidative hemolysis and lipid peroxidation by mepacrine. J Biochem. 1981;89(4):1143–8.PubMed
76.
Fujimoto Y, Tanioka H, Keshi I, Fujita T. The interaction between lipid peroxidation and prostaglandin synthesis in rabbit kidney-medulla slices. Biochem J. 1983;212(1):167–71.CrossRefPubMedPubMedCentral
77.
Shayevitz JR, McShane AJ, Traystman RJ, Gurtner GH. Mepacrine attenuates pulmonary vasoreactivity in rabbits. J Appl Physiol (1985). 1989;66(4):1921–6.
78.
McAnulty JF, Huang XQ. The effects of administering quinacrine during ultraprofound hypothermia on warm ischemic kidney cortex tissue. J Pharmacol Exp Ther. 1996;277(2):691–9.PubMed
79.
Al-Otaibi KE, Al Elaiwi AM, Tariq M, Al-Asmari AK. Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev. 2012;2012:831748. doi:10.​1155/​2012/​831748. Epub 2012 Oct 10.CrossRefPubMedPubMedCentral
80.
Ayvaz S, Aksu B, Kanter M, Uzun H, Erboga M, Colak A, Basaran UN, Pul M. Preventive effects of hyperbaric oxygen treatment on glycerol-induced myoglobinuric acute renal failure in rats. J Mol Histol. 2012;43(2):161–70. doi:10.​1007/​s10735-012-9391-5. Epub 2012 Feb 7.CrossRefPubMed
81.
Humes HD. Role of calcium in pathogenesis of acute renal failure. Am J Physiol. 1986;250(4 Pt 2):F579–89.PubMed
82.
Razzak AA, Mousah HA, Althamir SN. Nifedipine, calcium channel blocker against glycerol-induced acute renal failure in rats. Kufa Med J. 2004;7(1):1–4.
83.
84.
Salahudeen AK, Wang C, Bigler SA, Dai Z, Tachikawa H. Synergistic renal protection by combining alkaline-diuresis with lipid peroxidation inhibitors in rhabdomyolysis: possible interaction between oxidant and non-oxidant mechanisms. Nephrol Dial Transplant. 1996;11:635–42.CrossRefPubMed
85.
Najafzadeh H, Razijalali M, Morovvati H, Navvabi L. Evaluation the effect of cimetidine, estradiol and vitamin E on myoglobinuric renal toxicity in rats. Am Eurasian J Toxicol Sci. 2011;3(3):177–83.
86.
Kaya O, Aydogdu N, Tastekin E, Karadag CH, Unduz OG, Sut N. Effects of losartan on glycerol-induced myoglobinuric acute renal failure in rats. Kafkas Univ Vet Fak Derg. 2013;19(2):253–8. doi:10.​9775/​kvfd.​2012.​7620.
87.
Papanicolaou N, Callard P, Bariety J, Milliez P. The effect of indomethacin and prostaglandin (PGE2) on renal failure due to glycerol in saline-loaded rats. Clin Sci Mol Med. 1975;49(5):507–10.PubMed
88.
Abdulkader RC, Yuki MM, Paiva AC, Marcondes M. Prolonged inhibition of angiotensin II attenuates glycerol-induced acute renal failure. Braz J Med Biol Res. 1988;21(2):233–9.PubMed
89.
Nakamura H, Nemenoff RA, Gronich JH, Bonventre JV. Subcellular characteristics of phospholipase A2 activity in the rat kidney. Enhanced cytosolic, mitochondrial, and microsomal phospholipase A2 enzymatic activity after renal ischemia and reperfusion. J Clin Invest. 1991;87(5):1810–8.CrossRefPubMedPubMedCentral
90.
Worrell RT, Bao HF, Denson DD, Eaton DC. Contrasting effects of cPLA2 on epithelial Na + transport. Am J Physiol Cell Physiol. 2001;281(1):C147–56.PubMed
91.
Filippov A, Skatova G, Porotikov V, Kobrinsky E, Saxon M. Ca2 + −antagonistic properties of phospholipase A2 inhibitors, mepacrine and chloroquine. Gen Physiol Biophys. 1989;8(2):113–8.PubMed
92.
de la Peña P, Reeves JP. Inhibition and activation of Na + −Ca2+ exchange activity by quinacrine. Am J Physiol. 1987;252(1 Pt 1):C24–9.PubMed
Metadata
Title
Protective effect of quinacrine against glycerol-induced acute kidney injury in rats
Authors
Abdulrahman K. Al Asmari
Khalid Tariq Al Sadoon
Ali Ahmed Obaid
Deivakadatcham Yesunayagam
Mohammad Tariq
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0450-8

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue

Research article

Symptom burden in chronic kidney disease; a population based cross sectional study

Research article

On-line hemodiafiltration did not induce an overproduction of oxidative stress and inflammatory cytokines in intensive care unit-acute kidney injury

Case report

Novel mutation in the SLC12A3 gene in a Sri Lankan family with Gitelman syndrome & coexistent diabetes: a case report

Case report

Nephrolithiasis and Osteomalacia associated with adefovir-induced Fanconi syndrome in a patient with hepatitis B

Research article

Intensive procedure preferences at the end of life (EOL) in older Latino adults with end stage renal disease (ESRD) on dialysis

Research article

Comparison of equations for estimating glomerular filtration rate in screening for chronic kidney disease in asymptomatic black Africans: a cross sectional study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits